Stock Region Penny Picks
Stay Ahead. Stay Smart..
Stock Region Penny Picks Watchlist Newsletter
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: Before we dig into today's buzzworthy watchlist, a quick reminder—this newsletter is for informational purposes only and should not be taken as financial advice. Always do your due diligence before making any investment decisions. Now, let's get into it!
1. $EVOK - A Patent Win for Evoke Pharma
Evoke Pharma just listed a new patent for GIMOTI® in the FDA Orange Book. Translation? This could fortify their competitive edge and give their diabetic treatment product a longer runway. Patents equate to protection, and in the pharmaceutical world, that’s pure gold. Keep an eye here if you're bullish on biotech underdogs.
Opinion: Could this be the fresh momentum $EVOK needs to break out of its slump? Time will tell, but this is definitely one to keep on your radar.
2. $APM - DiamiR and Aptorum Score Big in New York
DiamiR Biosciences and Aptorum Group just gained New York State approval for APOE genotyping tests. This approval could mark a massive step forward in Alzheimer’s detection and treatment initiatives.
Analyst Vibes: Healthcare technology remains a high-stakes, high-reward sector. $APM is making the right moves, and this approval shows they’re playing chess, not checkers.
3. $REKR - Rekor Systems is Redefining Traffic Management
Rekor is set to debut a new line of secure, cloud-based tools for traffic and infrastructure management at the ITS World Congress 2025. They're pitching smarter planning and real-time incident reporting. Think about it—better roads, less traffic, fewer headaches. Who wouldn’t root for that?
Personal Take: Smart infrastructure is the future, and $REKR is positioning itself as a leader here. As cities get smarter, so might your portfolio.
4. $PTIX - Protagenic Therapeutics Makes Headway in Mood Disorders
With $PTIX advancing its PT00114 drug into multiple-dose Phase 1 trials, they’re gearing up for a Phase 2 focus on stress and mood disorders. Mental health treatment is a vital and underexplored market—this could be their chance to shine.
Gut Check: This space is ripe for disruption. If $PTIX delivers, they might just be on the brink of something enormous.
5. $PMEC - Primech AI’s Bathroom Robots Take Center Stage
AI meets hygiene! Primech AI has unveiled HYTRON, an autonomous bathroom-cleaning robot set to revolutionize cleanliness with next-gen tech. Yes, you read that right—bathroom cleaning robots.
Commentary: Is $PMEC the unsung hero of AI innovation? Sure, it’s niche, but when you think of the breadth of AI applications, this could be the tip of the iceberg.
6. $RENT - Rent the Runway Expands Its Strategy
Good news for fashionistas (and shareholders): Rent the Runway is rolling out a growth recapitalization and reimagining its expansion strategy. Will this pivot help them finally turn a corner in profitability?
Opinionated Take: If retail rebounds, $RENT could bounce back stronger than some skeptics think. But proceed with caution—this isn't a risk-free catwalk.
7. $VELO - Velo3D Partners With the U.S. Navy
3D printing gets an epic spotlight as Velo3D partners with the U.S. Navy to manufacture critical ship components. Maritime operations might never be the same.
My Two Cents: The demand for precision manufacturing in defense is massive, and this partnership highlights the trust placed in $VELO’s technology. Definitely worth a closer look.
8. $AEMD - A Wild Trading Day Without News
$AEMD soared over 129% to $2.59 on significant volume, despite no released news. It seems likely the offering announcement yesterday sparked speculative trading.
Cautionary Note: This kind of volatility is thrilling but unpredictable. If you jump on, make sure you’ve got a strategy.
9. $NCPL - Canceling the Offering
Goodbye, uncertainty. Netcapital ($NCPL) canceled its recent offering, a move that may restore investor confidence in the short term.
Quick Take: For some, this is a relief. For others, it raises questions about future funding strategies. Tread lightly.
10. $CYCU & $STRR Updates
$CYCU is back in compliance with Nasdaq listing requirements, inching further from danger territory. Summer comeback vibes?
$STRR stockholders approved a merger agreement during the special stockholder meeting. This kind of development could mean big things are ahead for Star Equity.
Final Thoughts: Compliance and mergers may not be sexy headlines, but they're critical for long-term success. Sometimes boring is good.
Until next time, Stock Region family—stay smart and watch those markets! 👀
Disclaimer: All investments carry risks. This newsletter contains opinions and should not be your sole source of financial decisions. Do your research, diversify your portfolio, and stay informed.